Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Preparation for Beactica’s EIC Transition application

Reference number
Coordinator Beactica Therapeutics AB
Funding from Vinnova SEK 300 000
Project duration June 2025 - September 2025
Status Ongoing
Venture Global cooperation 2025
Call Planning grant for international proposal 2025

Purpose and goal

The main goal of the project is to develop a strong application that will have a strong chance of obtaining a grant in the competitive EIC Transition programme.

Expected effects and result

Funding from EICT enables the completion of the preclinical block for the development of Beactica´s drug against glioblastoma, as well as the development of biomarkers to identify patients who can be helped by treatment with this drug.

Planned approach and implementation

The Proposal will be written in collaboration with an established project partner and a grant-writing consultancy firm.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 24 June 2025

Reference number 2025-01510